Takeda’s once-daily psoriasis pill zasocitinib, entered FDA Priority Review with a target decision date in the first quarter of 2027.
Recent Posts
- FDA Grants Breakthrough Status to a Phage Treatment for Drug Resistant Staph Bloodstream Infections Ahead of Phase 3
- People with ADHD Had Nearly Double the Odds of Constipation in a Review Covering 1.9 Million People
- Legionnaires Cases Rose 6.6-Fold in Two Decades and a New Analysis Points to Heat, Rain and Traffic
- Once Daily Psoriasis Pill from Takeda Enters Priority FDA Review with a Decision Expected in Early 2027
- A Single Dose of Pharmaceutical LSD Cut Anxiety Scores Five Points Below Placebo in Phase 3 Trial
Archives
- September 2026
- August 2026
- July 2026
- June 2026
- May 2026
- February 2026
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- February 2024
- January 2024
- December 2023
- September 2023
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
Recent Comments